Novavax (NVAX) Competitors $7.55 +0.08 (+1.07%) Closing price 04:00 PM EasternExtended Trading$7.58 +0.03 (+0.40%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. MRNA, OCGN, VXRT, JNJ, PFE, ALKS, LGND, FOLD, BCRX, and CLDXShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Moderna (MRNA), Ocugen (OCGN), Vaxart (VXRT), Johnson & Johnson (JNJ), Pfizer (PFE), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector. Novavax vs. Its Competitors Moderna Ocugen Vaxart Johnson & Johnson Pfizer Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Do analysts rate NVAX or MRNA? Novavax presently has a consensus target price of $14.29, indicating a potential upside of 89.21%. Moderna has a consensus target price of $42.88, indicating a potential upside of 77.27%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novavax is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 3 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do institutionals & insiders hold more shares of NVAX or MRNA? 53.0% of Novavax shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is NVAX or MRNA more profitable? Novavax has a net margin of 39.20% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Novavax39.20% -142.33% 28.65% Moderna -94.31%-25.96%-20.09% Does the media prefer NVAX or MRNA? In the previous week, Novavax had 16 more articles in the media than Moderna. MarketBeat recorded 28 mentions for Novavax and 12 mentions for Moderna. Novavax's average media sentiment score of 1.10 beat Moderna's score of 0.96 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, NVAX or MRNA? Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$682.16M1.80-$187.50M$2.283.31Moderna$3.24B2.91-$3.56B-$7.53-3.21 Which has more volatility & risk, NVAX or MRNA? Novavax has a beta of 2.68, indicating that its share price is 168% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. SummaryNovavax beats Moderna on 11 of the 17 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio3.317.4762.2622.40Price / Sales1.80396.81537.34111.77Price / CashN/A43.5325.7028.92Price / Book32.838.1011.196.58Net Income-$187.50M-$53.35M$3.28B$265.84M7 Day Performance0.67%-0.14%0.15%-0.07%1 Month Performance15.09%9.18%8.34%5.83%1 Year Performance-39.01%7.53%54.21%17.88% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax4.6032 of 5 stars$7.55+1.1%$14.29+89.2%-39.7%$1.21B$682.16M3.311,990Positive NewsAnalyst RevisionMRNAModerna4.548 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$9.86B$3.24B-3.375,800OCGNOcugen1.2296 of 5 stars$1.04+3.0%$6.00+476.9%-21.5%$303.99M$4.05M-5.2080News CoverageVXRTVaxart2.3334 of 5 stars$0.35+1.8%$2.00+466.3%-55.0%$80.86M$47.40M-1.31120News CoverageGap DownJNJJohnson & Johnson4.6126 of 5 stars$178.53-0.4%$176.29-1.3%+6.8%$429.96B$88.82B19.09138,100Positive NewsPFEPfizer4.8049 of 5 stars$25.15-2.8%$28.12+11.8%-14.7%$142.99B$63.63B13.3881,000Trending NewsALKSAlkermes4.8294 of 5 stars$29.00-2.5%$41.08+41.7%+1.8%$4.79B$1.56B13.941,800News CoveragePositive NewsLGNDLigand Pharmaceuticals3.5975 of 5 stars$158.79-0.2%$157.00-1.1%+52.8%$3.11B$167.13M-39.7080Positive NewsAnalyst ForecastShort Interest ↑FOLDAmicus Therapeutics4.0725 of 5 stars$7.48-1.7%$16.22+116.9%-34.6%$2.31B$528.29M-62.33480News CoverageAnalyst DowngradeBCRXBioCryst Pharmaceuticals4.0797 of 5 stars$8.39-2.0%$16.70+99.0%-4.4%$1.76B$557.51M-46.61530News CoveragePositive NewsCLDXCelldex Therapeutics2.2415 of 5 stars$21.93-2.4%$46.67+112.8%-46.6%$1.46B$7.02M-7.29150Positive News Related Companies and Tools Related Companies Moderna Alternatives Ocugen Alternatives Vaxart Alternatives Johnson & Johnson Alternatives Pfizer Alternatives Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVAX Stock Alerts